Arcellx strengthens case for CAR T adaptor platform with updated Phase I MM data from BCMA program

The latest cut of Arcellx’s Phase I data for its BCMA-directed CAR T cell therapy maintains the candidate’s position as one of the top-performing CAR Ts against the target. 

In an abstract released ahead of the 2021 American Society of Clinical Oncology (ASCO) meeting, Arcellx Inc. reported a 100% overall response rate (ORR) from the first 12 evaluable relapsed and refractory MM patients in the first two dose cohorts of the open-label trial testing CART-ddBCMA...